Skip to main content
SpringerLink
Log in

High-dose chemotherapy in non-Hodgkin’s lymphoma

  • Chapter
Advances in Lymphoma Research

Part of the book series: Cancer Treatment and Research ((CTAR,volume 85))

  • 41 Accesses

Abstract

The first reports of high-dose chemotherapy (HDC) and bone marrow transplantation (BMT) in non-Hodgkin’s lymphoma (NHL) were published 15 years ago, but the indications of HDC in the treatment of NHL still remains controversial [1,2]. The Consensus Conference on the Indications of HDC, which was held in Lyon in 1993, has concluded that there was no clinical situation in which HDC could be considered as a standard treatment in NHL [1,2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Coiffier B, Philip T, Burnett AK, Symann M (1994). Consensus conference on Intensive Chemotherapy plus Hematopoietic Stem Cell Transplantation in Malignancies, June 4-6, 1994. Lyon, France. J Clin Oncol 12:226–231.

    PubMed  CAS  Google Scholar 

  2. Coiffier B, Philip T, Burnett AK, Symann M (1994). Consensus conference on Intensive Chemotherapy plus Hematopoietic Stem Cell Transplantation in Malignancies, June 4-6, 1994. Lyon, France. Ann Oncol 5:19–23.

    PubMed  CAS  Google Scholar 

  3. Weisenburger DD (1994). Epidemiology of non Hodgkin’s lymphoma: recent findings regarding an emerging epidemic. Ann Oncol 5(Suppl 1):S19–S24.

    Google Scholar 

  4. Fisher RL, Gaynor ER, Dahlberg S, et al. (1993). Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non Hodgkin’s lymphoma. N Engl J Med 328:1002–1006.

    Article  PubMed  CAS  Google Scholar 

  5. Horning SJ (1993). Low-grade lymphoma 1993: state of the art. Ann Oncol (Suppl 2):S23–S27.

    Google Scholar 

  6. Coltman CA, Dahlberg S, Jones SE, et al. (1987). CHOP is curative in thirty percent of patients with large cell lymphomas: a twelve-year Southwest Oncology Group follow-up. Proc Am Soc Clin Oncol 5:197 (abstract).

    Google Scholar 

  7. Klimo P, Connors JM (1985). MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann Intern Med 102:596–602.

    PubMed  CAS  Google Scholar 

  8. Skarin AT, Canellos GP, Rosenthal DS, et al. (1983). Improved prognosis of diffuse histiocytic and undifferenciated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol 1:91–96.

    PubMed  CAS  Google Scholar 

  9. Coiffier B, Tilly H, Bosly A, Sebban C, Herbrecht R, Gisselbrecht (1993). Long term follow-up of the 737 aggressive lymphoma patients treated with the LNH84 protocol: very few relapses after 5 years. Blood 82:444a (abstract).

    Google Scholar 

  10. Appelbaum FR, Herzig GP, Ziegler JL, et al. (1978). Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood 52:85–95.

    PubMed  CAS  Google Scholar 

  11. Appelbaum FR, Thomas ED (1983). Review of the use of marrow transplantation in the treatment of non Hodgkin’s lymphoma. J Clin Oncol 1:440–447.

    PubMed  CAS  Google Scholar 

  12. Gulati SC, Shank B, Black L, et al. (1988). Autologous bone marrow transplantation for patients with poor prognosis lymphoma. J Clin Oncol 6:1303–1313.

    PubMed  CAS  Google Scholar 

  13. Gianni AM, Bregni M, Siena S, et al. (1991). Prospective randomized comparison of MACOP-B vs rGM-CSF supported high dose sequential myeloablative chemotherapy in diffuse large cell lymphoma. Proc Am Soc Clin Oncol 10:274 (abstract).

    Google Scholar 

  14. Haioun C, Lepage E, Gisselbrecht C, et al. (1993). Comparison of autologous bone marrow transplantation with sequential chemotherapy for aggressive non Hodgkin’s lymphoma (NHL) in first complete remission: a study on 464 patients (LNH87 protocol). Blood 82:87a (abstract).

    Google Scholar 

  15. Tura S, Zinzani PL, Mazza P, et al. (1992). ABMT vs DHAP in residual disease following third generation regimens for agressive non Hodgkin’s lymphoma. Blood 80(Suppl 1):157 (abstract).

    Google Scholar 

  16. Fisher R, DeVita VT, Johnson BL, Simon R, Young RC (1977). Prognostic factors for response and survival in adults with advanced non Hodgkin’s lymphoma. Am J Med 63:177–180.

    Article  PubMed  CAS  Google Scholar 

  17. Cabanillas F, Burke JS, Smith TL, Moon ME, Butler JJ, Rodriguez V (1978). Factors predicting for response and survival in adults with advanced non Hodgkin’s lymphoma. Arch Intern Med 138:413–417.

    Article  PubMed  CAS  Google Scholar 

  18. Swan F Jr, Velasquez WS, Tucker S, et al. (1989). A new serologic staging system for large cell lymphomas based on initial β2 microglobulin and lactate dehydrogenase levels. J Clin Oncol 7:1518–1527.

    PubMed  Google Scholar 

  19. Coiffier B, Gisselbrecht C, Vose JM, et al. (1991). Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d’Etude des lymphomes Agressifs. J Clin Oncol 9:211–219.

    PubMed  CAS  Google Scholar 

  20. Shipp MA, Harrington DP, Anderson JR, et al. (1993). A predictive model for aggressive NHL: the International Non Hodgkin’s Lymphoma Prognostic Factor Project. N Engl J Med 329:987–992.

    Article  Google Scholar 

  21. Fischer RI, DeVita VT, Hubbard SM, et al. (1983). Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med 93:304–309.

    Google Scholar 

  22. Philip T, Hartmann O, Biron P, et al. (1988). High dose therapy and autologous bone marrow transplantation in partial remission after first line induction therapy for diffuse non Hodgkin’s lymphoma. J Clin Oncol 6:1118–1124.

    PubMed  CAS  Google Scholar 

  23. Hagenbeek A, Verdonck L, Sonneveld P, Schouten H, van Imhoff G, van Putten W (1993). CHOP chemotherapy vs autologous BMT in slowly responding patients with intermediate and high grade malignant non Hodgkin’s lymphoma: results from a prospective randomized phase III trial in 294 patients. Blood 82:332a (abstract).

    Google Scholar 

  24. Surbone A, Longo D, De Vita C Jr, et al. (1988). Residual masses in aggressive non Hodgkin’s lymphoma after combination chemotherapy: signification and management. J Clin Oncol 6:1832–1837.

    PubMed  CAS  Google Scholar 

  25. Cohen-Haguenauer O, Brice P, Gaci M, et al. (1993). Apport de la scintigraphie au gallium-67 dans les lymphomes malins. Presse Med 22:521–525.

    PubMed  CAS  Google Scholar 

  26. Philip T, Armitage O, Spitzer G, et al. (1987). High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high grade non Hodgkin’s lymphoma. N Engl J Med 316:1493–1498.

    Article  PubMed  CAS  Google Scholar 

  27. Phillips GL, Herzig RH, Lazarus HM, et al. (1983). Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation, and transplantation of cryopreserved autologous marrow. N Engl J Med 310:1557–1561.

    Article  Google Scholar 

  28. Takvorian T, Canellos GP, Ritz J, et al. (1987). Prolonged disease free survival after autologous bone marrow transplantation in patients with non Hodgkin’s lymphoma with a poor prognosis. N Engl J Med 316:1499–1505.

    Article  PubMed  CAS  Google Scholar 

  29. Goldstone AH, MacMillan AK, Chopra R (1992). High dose therapy for the treatment of non Hodgkin’s lymphoma. In Armitage JO, Antmann KA (eds), High Dose Cancer Therapy: Pharmacology Haematopoietins, Stem Cells. Baltimore: Williams and Wilkins, pp. 662–670.

    Google Scholar 

  30. Bosly A, Coiffier B, Gisselbrecht C, et al. (1992). Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. J Clin Oncol 10:1615–1623.

    PubMed  CAS  Google Scholar 

  31. Philip T, Guglielmi A, Hagenbeek A, et al. (1992). The Parma international randomized prospective study in relapsed non Hodgkin’s lymphoma: second interim analysis of 172 patients. Blood 80:67a (abstract).

    Google Scholar 

  32. Appelbaum FR, Deisseroth AB, Graw RG, et al. (1987). Prolonged complete remission following high dose chemotherapy of Burkitt’s lymphoma in relapse. Cancer 41:1059–1063.

    Article  Google Scholar 

  33. Philip T, Pinkerton R, Hartmann O, et al. (1986). The role of massive therapy with autologous bone marrow transplantation in Burkitt’s lymphoma. Clin Hematol 15:205–218.

    Article  CAS  Google Scholar 

  34. Blay J-Y, Philip T (1992). High dose therapy in Burkitt’s lymphoma. In Armitage JO, Antmann KA (eds), High Dose Cancer Therapy: Pharmacology Haematopoietins, Stem Cells. Baltimore: Williams and Wilkins, pp. 677–689.

    Google Scholar 

  35. Patte C, Michon J, Bouffet E, et al. (1992). High survival of childhood B-cell lymphoma and leukemia (ALL) as result of the LMB89 protocol of the SFOP. Proc Am Soc Clin Oncol 11:340 (abstract).

    Google Scholar 

  36. Patte C, Leverger G, Rubie H, et al. (1993). High cure rate in B-cell (Burkitt’s) leukemia in the LMB89 protocol of the SFOP. Proc Am Soc Clin Oncol 12:317 (abstract).

    Google Scholar 

  37. Philip T, Meckenstock R, Deconnick E, et al. (1992). Treatment of poor prognosis Burkitt’s lymphoma in adults with the Societe Francaise d’Oncologie Pediatrique LMB Protocol — a study of the Federation Nationale des Centres de Lutte Contre le Cancer (FNLCC). Eur J Cancer 28A: 1954–1959.

    Article  PubMed  CAS  Google Scholar 

  38. Ostronoff M, Soussain C, Zambon E, et al. (1992). Burkitt’s lymphoma in adults: a retrospective study of 46 cases. Nouv Rev Fr Hematol 34:389–397.

    PubMed  CAS  Google Scholar 

  39. Patte C, Philip T, Rodary C, et al. (1991). High survival rate in advanced stage B cell lymphoma and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 9:123–132.

    PubMed  CAS  Google Scholar 

  40. Philip T, Hartmann O, Pinkerton R, et al. (1993). Curability of relapsed childhood B-cell non-Hodgkin’s lymphoma after intensive first line therapy: a report from the Societe Francaise d’Oncologie Pediatrique. Blood 81:2003–2006.

    PubMed  CAS  Google Scholar 

  41. Coleman CN, Picozzi VJ, Cox RS, et al. (1987). Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 4:399–404.

    Google Scholar 

  42. Morel P, Lepage E, Brice P, et al. (1992). Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. J Clin Oncol 10:1078–1085.

    PubMed  CAS  Google Scholar 

  43. Milpied N, Ifrah N, Kuentz M, et al. (1989). Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remission. Br J Haematol 73:82–87.

    Article  PubMed  CAS  Google Scholar 

  44. Santini G, Congui AM, Coser P, et al. (1991). Autologous bone marrow transplantation for adult advanced stage adult non Hodgkin’s lymphoma in first complete remission: a study of the NHLGSG. Leukemia 5(Suppl 1):42–45.

    PubMed  Google Scholar 

  45. Verdonck LF, Dekker AW, Gijsberg C, et al. (1992). Autologous bone marrow transplantation for adult poor risk lymphoblastic lymphoma in first remission. J Clin Oncol 10:644–648.

    PubMed  CAS  Google Scholar 

  46. Chopra R, Goldstone AH, Pearce R, et al. (1992). Autologous versus allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 10:1690–1695.

    PubMed  CAS  Google Scholar 

  47. Horning SJ, Rosenberg SA (1984). The natural history of initially untreated low grade lymphoma non Hodgkin’s lymphoma. N Engl J Med 311:1471–1475.

    Article  PubMed  CAS  Google Scholar 

  48. Lister TA, Cullen MH, Beard MEJ, et al. (1978). Comparison of combined and single agent chemotherapy in non Hodgkin’s lymphoma of favorable histological type. Br Med J 1:533–537.

    Article  PubMed  CAS  Google Scholar 

  49. Young RC, Longo DL, Glatstein E, et al. (1988). The treatment of indolent lymphoma: watchful waiting vs aggressive combined modality treatment. Semin Haematol 25:11–16.

    CAS  Google Scholar 

  50. Mac Laughlin P, Fuller LM, Velasquez WS, et al. (1987). Stage III follicular lymphoma: durable remissions with a combined chemotherapy-radiotherapy regimen. J Clin Oncol 5:867–874.

    Google Scholar 

  51. Matis LA, Young RS, Longo DL (1986). Nodular lymphoma: current concepts. CRC Crit Rev Oncol Hematol 5:171–181.

    Article  CAS  Google Scholar 

  52. Smalley RV, Andersen JW, Hawkins MJ, et al. (1992). Interferon alfa combined with cyto-toxic chemotherapy for patients with non-Hodgkin’s lymphoma. N Engl J Med 327:1336–1341.

    Article  PubMed  CAS  Google Scholar 

  53. Andersen JW, Smalley RV (1993). Interferon alfa plus chemotherapy for non-Hodgkin’s lymphoma: five-year follow-up. N Engl J Med 329:1821–1822 (letter).

    Article  PubMed  CAS  Google Scholar 

  54. Solal-Celigny P, Lepage E, Brousse N, et al. (1993). Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d’Etude des Lymphomes de l’Adulte. N Engl J Med 329:1608–1614.

    Article  PubMed  CAS  Google Scholar 

  55. Gribben JG, Freedman AS, Neuberg D, et al. (1991). Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325:1525–1533.

    Article  PubMed  CAS  Google Scholar 

  56. Gribben JG, Freedman AS, Woo SD, et al. (1991). All advanced stage non-Hodgkin’s lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 78:3275–3280.

    PubMed  CAS  Google Scholar 

  57. Berinstein N, Reis MD, Ngan BY, et al. (1992). Detection of occult lymphoma in the peripheral blood and bone marrow of patients with untreated early and advanced stage follicular lymphoma. Proc Am Soc Clin Oncol 12:369 (abstract).

    Google Scholar 

  58. Freedman AS, Ritz J, Neuberg D, et al. (1991). Autologous bone marrow transplantation in 69 patients with a history of low grade B cell non Hodgkin’s lymphoma. Blood 77:2524–2529.

    PubMed  CAS  Google Scholar 

  59. Brenner MK, Rill DR, Moen RC, et al. (1993). Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341:85–86.

    Article  PubMed  CAS  Google Scholar 

  60. Bierman P, Vose J, Armitage JO, et al. (1992). High dose chemotherapy followed by autologous hematopoietic rescue for follicular low grade lymphoma. Proc Am Soc Clin Oncol 11:317 (abstract).

    Google Scholar 

  61. Freedman A, Nadler LM (1992). Bone marrow transplantation in low grade non Hodgkin’s lymphoma. Marrow Transplant Rev 2:33–38.

    Google Scholar 

  62. Fouillard L, Gorin NC, Laporte JP, et al. (1991). Feasibility of autologous bone marrow transplantation for early consolidation of follicular non-Hodgkin’s lymphoma. Eur J Haematol 46:279–284.

    Article  PubMed  CAS  Google Scholar 

  63. Schouten HC, Colombat P, Verdonck P, et al. (1994). Autologous bone marrow transplantation for low grade lymphoma: the European Bone Marrow Transplant Group experience. Ann Oncol 5(Suppl 2):S147–S150.

    Google Scholar 

  64. Weisdorf DJ, Anerson JW, Glick JH, et al. (1992). Survival after relapse of low grade non Hodgkin’s lymphoma: implication for bone marrow transplantation. J Clin Oncol 10:942–947.

    PubMed  CAS  Google Scholar 

  65. Rohatiner AZS, Price CGA, Arnott S, et al. (1990). Ablative therapy with autologous bone marrow transplantation as consolidation of remission in patients with follicular lymphoma. In Dicke KA, Armitage JO, Discke-Evinger MJ (eds), Autologous Bone Marrow Transplantation: Proceedings of the Fifth International Symposium. Omaha: University of Nebraska Medical Center, pp. 465–470.

    Google Scholar 

  66. Rohatiner AZS, Freedman A, Nadler L, et al. (1994). Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma. Ann Oncol 5(Suppl 2):S143–S146.

    Google Scholar 

  67. Colombat P, Binet C, Linassier C, et al. (1992). High dose chemotherapy with autologous marrow transplantation in follicular lymphomas. Leuk Lymphoma 7:3–6.

    Article  PubMed  Google Scholar 

  68. Bastion Y, Brice P, Sonet A, et al. (1994). Autologous peripheral blood stem cell transplantation (PBSCT) in 40 patients with advanced follicular lymphoma. Proc Am Soc Clin Oncol 13:1255 (abstract).

    Google Scholar 

  69. Lungren JH, Hansen RM, Chitambar CR, et al. (1991). Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA identical and alternative donors. J Clin Oncol 9:1848–1859.

    Google Scholar 

  70. Jones RJ, Ambinder RF, Piantadosi S, Santos GW (1991). Evidence of a graft versus lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649–653.

    PubMed  CAS  Google Scholar 

  71. Appelbaum FR, Sullivan KM, Buckner CD, et al. (1987). Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation and marrow transplantation. J CLin Oncol 5:1340–1347.

    PubMed  CAS  Google Scholar 

  72. Phillips GL, Herzig RH, Lazarus HM, et al. (1986). High dose chemotherapy, fractionated total body irradiation, and allogeneic marrow transplantation for malignant lymphoma. J Clin Oncol 4:480–488.

    PubMed  CAS  Google Scholar 

  73. Klingemann HG, Grigg A, Wilkie-Boyd K, et al. (1991). Treatment with recombinant interferon alpha ealry after bone marrow transplantation in patients at high risk for relapse. Blood 78:3306–3311.

    PubMed  CAS  Google Scholar 

  74. Gottlieb DJ, Prentice HG, Geslop HE, et al. (1989). Effects of recombinant IL-2 administration on cytotoxic function following high dose chemo-radiotherapy for hematological malignancy. Blood 74:2335–2342.

    PubMed  CAS  Google Scholar 

  75. Kennedy MJ, Vogelsang GB, Jones RJ, et al. (1994). Phase I trial of interferon gamma to potentiate cyclosporine induced graft versus host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 12:249–257.

    PubMed  Google Scholar 

  76. Kessinger A, Armitage JO, Smith DM, et al. (1989). High dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 74:1260–1265.

    PubMed  CAS  Google Scholar 

  77. Brice P, Marolleau JP, Dombret H, et al. (1992). Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas. Bone Marrow Transplant 9:337–342.

    PubMed  CAS  Google Scholar 

  78. Vose JM, Anderson JR, Kessinger A, et al. (1993). High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin’s lymphoma. J Clin Oncol 11:1846–1851.

    PubMed  CAS  Google Scholar 

  79. Liberti G, Pearce R, Taghipour G, Majolino I, Goldstone AH (1994). Comparison of peripheral blood stem cell and autologous bone marrow transplantation for lymphoma patients: a case control analysis of the EBMT registry data. Ann Oncol 5(S2):S151–S153.

    Google Scholar 

  80. Schwartzenberg LS, Birch R, Haselton B, et al. (1992). Peripheral blood stem cell mobilisation by chemotherapy with and without rG-CSF J Haematother 1:317–327.

    Article  Google Scholar 

  81. Sheridan WP, Begley CG, Juttner CA, et al. (1992). Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339:640–644.

    Article  PubMed  CAS  Google Scholar 

  82. Nemunaitis J, Rabinowe SN, Singer JW, et al. (1991). Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 324:1773–1778.

    Article  PubMed  CAS  Google Scholar 

  83. Gorin N-C, Coiffier B, Hayat M, et al. (1992). Recombinant human GM-CSF after high dose chemotherapy and autologous bone marrow transplantation with unpurged and pruged marrow in non Hodgkin’s lymphoma. Blood 80:1149–1157.

    PubMed  CAS  Google Scholar 

  84. Gisselbrecht C, Prentice HG, Bacigalupo A, Biron P, Milpied N, Rubie H, Cunningham D, Legros M, Pico JL, Linch DC, Burnett AK, Scarffe JH, Siegert W, Yver A (1994). Placebo controlled phase III trial of lenograstim in bone marrow transplantation. Lancet 343:696–700.

    Article  PubMed  CAS  Google Scholar 

  85. Spitzer G, Adkins DR, Spencer V, et al. (1994). Randomized study of growth factors post-peripheral blood stem cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 12:661–670.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Jean-Yves Blay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thierry O. Philip
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Hematology, M.D. Anderson Cancer Center, Houston, Texas, USA

    Fernando Cabanillas M.D.  & M. Alma Rodriguez M.D.  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media New York

About this chapter

Cite this chapter

Blay, JY., Philip, T.O. (1997). High-dose chemotherapy in non-Hodgkin’s lymphoma. In: Cabanillas, F., Rodriguez, M.A. (eds) Advances in Lymphoma Research. Cancer Treatment and Research, vol 85. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4129-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-4129-5_7

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6851-9

  • Online ISBN: 978-1-4615-4129-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation